Update from Marathon Pharmesuticals

Two pharmaceutical companies, Sarepta and Marathon, presented updates on medicines for DMD patients.  Because of several controversial issues around pricing, Marathon was under pressure to explain their pricing model for a product that had essentially been on the market for ~40 years.  In an effort to slow down and hear customers, the CEO of Marathon sent Pat Furlong an email with a temporary measure aimed at allaying concerns about an immediate price hike for US patients who needed the medication.

The following video is Pat Furlong reading a letter from the CEO.

Here is a letter from Marathon to the DMD community:

Here, also, is a relevant page on Marathon's website: http://marathonpharma.com/treatments/ensuring-access/

Christopher JonesPPMD, Advocacy, Mitchell's Journey In ActionComment